🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Flomoxef

    Takeda Pharmaceuticals International AG

    Urinary Tract Infection

    phase 3 small molecule terminated

    1 trial

  2. Fosrenol (Lanthanum Carbonate)

    Takeda Pharmaceuticals International AG

    Chronic Kidney Disease, Stage 5

    phase 3 small molecule completed

    1 trial

  3. GA-GCB (velaglucerase alfa)

    Takeda Pharmaceuticals International AG

    Gaucher Disease

    phase 3 mab completed

    1 trial

  4. GLASSIA

    Takeda Pharmaceuticals International AG

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  5. GLASSIA

    Takeda Pharmaceuticals International AG

    Graft Versus Host Disease

    phase 3 mab terminated

    1 trial

  6. HYQVIA

    Takeda Pharmaceuticals International AG

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    phase 3 mab completed

    2 trials

  7. High Dose Colchicine (4.8 mg total dose)

    Takeda Pharmaceuticals International AG

    Gout

    phase 3 small molecule completed

    1 trial

  8. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  9. HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  10. IBI363

    Takeda Pharmaceuticals International AG

    iO Resistant sqNSCLC

    phase 3 small molecule active

    1 trial

  11. IGI, 10%

    Takeda Pharmaceuticals International AG

    Multiple Myeloma

    phase 3 mab active

    1 trial

  12. IGSC 20% infusion

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Disease

    phase 3 mab completed

    1 trial

  13. IXAZOMIB

    Takeda Pharmaceuticals International AG

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 3 small molecule terminated

    1 trial

  14. Icatibant

    Takeda Pharmaceuticals International AG

    Angioedema

    phase 3 small molecule completed

    1 trial

  15. Icatibant

    Takeda Pharmaceuticals International AG

    Angiotensin Converting Enzyme Inhibitor Induced Angioedema

    phase 3 small molecule completed

    1 trial

  16. Icatibant

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema

    phase 3 small molecule completed

    3 trials

  17. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda Pharmaceuticals International AG

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  18. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda Pharmaceuticals International AG

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  19. Immune Globulin Infusion (Human), 10%

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  20. Immune Globulin Intravenous (Human), 10%

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  21. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda Pharmaceuticals International AG

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  22. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda Pharmaceuticals International AG

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  23. Immune Globulin Intravenous (Human), 10% Solution

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  24. Immune Globulin Intravenous (Human), 10% Solution

    Takeda Pharmaceuticals International AG

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources